What's Happening?
Summit Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for ivonescimab. The application sought approval for ivonescimab in combination
with platinum-containing chemotherapy for treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The FDA determined that the BLA cannot be approved in its current form, citing that the progression-free survival (PFS) benefit, in the absence of a statistically significant overall survival (OS) benefit, does not support a positive benefit-risk profile for approval. While the HARMONi study, which supported the BLA, met its PFS primary endpoint, the FDA requires statistically significant OS improvement for approval in this setting. Summit Therapeutics expressed disappointment but affirmed its commitment to advancing ivonescimab's development.
Why It's Important?
This FDA decision significantly impacts Summit Therapeutics and the broader oncology landscape, particularly for patients with advanced NSCLC. The rejection means that a potential new treatment option for a patient population with limited alternatives will not be immediately available in the U.S. The FDA's emphasis on statistically significant overall survival benefit underscores its rigorous standards for drug approvals, especially in life-threatening conditions like cancer. For Summit Therapeutics, this represents a setback in its commercialization efforts for ivonescimab in the U.S., potentially affecting its market position and investor confidence. The decision also highlights the challenges biopharmaceutical companies face in meeting stringent regulatory requirements, even when a drug shows promise in improving progression-free survival. The company's ongoing collaborations with other biopharmaceutical firms to test ivonescimab in various combinations and indications suggest a continued long-term strategy despite this immediate hurdle.
What's Next?
Summit Therapeutics will need to address the FDA's concerns outlined in the Complete Response Letter. This typically involves providing additional data, conducting further clinical trials, or re-evaluating the existing data to demonstrate a statistically significant overall survival benefit. The company has an expansive clinical development program for ivonescimab, including ongoing Phase III studies in other NSCLC settings, colorectal cancer, urothelial carcinoma, and renal cell carcinoma. Collaborations with AstraZeneca, Daiichi Sankyo, Revolution Medicines, GSK, and Arcus Biosciences are also underway to explore ivonescimab in combination with other novel compounds for various solid tumors. While ivonescimab was approved for marketing authorization in China in May 2024, its path to U.S. approval for this specific indication will require further engagement with the FDA and potentially more robust clinical evidence.
Beyond the Headlines
The FDA's decision on ivonescimab reflects a broader regulatory trend towards prioritizing overall survival as a critical endpoint for cancer therapies, particularly when considering accelerated approvals. While progression-free survival can indicate a delay in disease progression, overall survival directly measures the extension of a patient's life, which is often the ultimate goal in cancer treatment. This stance by the FDA could influence future clinical trial designs and drug development strategies across the pharmaceutical industry, pushing companies to focus more on demonstrating clear overall survival benefits early in their development programs. The case also highlights the global disparity in drug approvals, with ivonescimab already approved in China but facing hurdles in the U.S., underscoring different regulatory philosophies and patient needs across regions. The ongoing pursuit of novel bispecific antibodies like ivonescimab, which target multiple pathways (PD-1 and VEGF), remains a key area of innovation in oncology, aiming to overcome resistance and improve outcomes for patients.













